

| 論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁 | 雑誌名 |
|---|---------------------------------------|
| Takano, T; Tsurutani, J; Takahashi, M; Yamanaka, T; Sakai, K; Ito, Y; Fukuoka, J; Kimura, H; Kawabata, H; Tamura, K; Matsumoto, K; Aogi, K ; Sato, K; Nishio, K; Nakagawa, K; Saeki, T.A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.BREAST.2018 Aug;40(0);67-75 | BREAST |
| Kobayashi, S; Terashima, T; Shiba, S; Yoshida, Y; Yamada, I; Iwadou, S; Horiguchi, S; Takahashi, H; Suzuki, E; Moriguchi, M; Tsuji, K; Otsuka, T; Asagi, A ; Kojima, Y; Takada, R; Morizane, C; Mizuno, N; Ikeda, M; Ueno, M; Furuse, J.Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.CANCER SCIENCE.2018 Aug;109(8):2549-2557. | CANCER SCIENCE |
| Shibuya, H; Hijioka, S; Sakamoto, Y; Ito, T; Ueda, K; Komoto, I; Kobayashi, N; Kudo, A; Yasuda, H; Miyake, H; Arita, J; Kiritani, S; Ikeda, M; Imaoka, H; Ueno, M; Kobayashi, S; Furuta, M; Nagashio, Y; Murohisa, G; Aoki, T; Matsumoto, S; Motoya, M; Azemoto, N ; Itakura, J; Horiguchi, S; Yogi, T; Kawagoe, T; Miyaoka, Y; Imamura, F; Senju, M; Arioka, H; Hara, K; Imamura, M; Okusaka, T.Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.CANCER CHEMOTHERAPY AND PHARMACOLOGY.2018 Oct;82(4):661-668. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| Yamamoto, Y; Iwata, H; Ueno, T; Taira, N; Kashiwaba, M; Takahashi, M; Tada, H; Tsugawa, K; Toyama, T; Niikura, N; Hara, F ; Fujisawa, T; Yoshinami, T; Saji, S; Takano, T; Masuda, N; Morita, S; Toi, M; Ohno, S.A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Sep;48(9):855-859. | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| Yamaguchi, T; Mukai, H; Takahashi, M; Hara, F ; Yamauchi, C; Yamashita, S; Ushijima, T.Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial).JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Apr;48(4):388-391. | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| Ohtani, S; Nakayama, T; Yoshinami, T; Watanabe, K; Hara, F ; Sagara, Y; Kawaguchi, H; Higaki, K; Matsunami, N; Hasegawa, Y; Takahashi, M; Mizutani, M; Morimoto, T; Sato, M; Itoh, M; Morita, S; Masuda, N.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).BREAST CANCER.2018 Jul;25(4):438-446. | BREAST CANCER |
| Iwama, E; Sakai, K; Azuma, K; Harada, D ; Nosaki, K; Hotta, K; Nishio, M; Kurata, T; Fukuhara, T; Akamatsu, H; Goto, K; Shimose, T; Kishimoto, J; Nakanishi, Y; Nishio, K; Okamoto, I.Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.CANCER SCIENCE.2018 Dec;109(12):3921-3933. | CANCER SCIENCE |
| Haga, Y; Hato, S ; Ikenaga, M; Yamamoto, K; Tsuburaya, A; Doi, K; Ikejiri, K; Hirata, T; Yamamoto, M; Ishikawa, S; Takeuchi, H.Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer.EJSO.2018 Apr;44(4):515-523. | EJSO |
| Ozaka, M; Ishii, H ; Sato, T; Ueno, M; Ikeda, M; Uesugi, K; Sata, N; Miyashita, K; Mizuno, N; Tsuji, K; Okusaka, T; Furuse, J.A phase II study of modified FOLFIRINOX for chemotherapy-na < ve patients with metastatic pancreatic cancer.CANCER CHEMOTHERAPY AND PHARMACOLOGY.2018 Jun;81(6):1017-1023. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |

| | |
|--|---------------------------------------|
| Nakachi, K; Konishi, M; Ikeda, M; Mizusawa, J; Eba, J; Okusaka, T; Ishii, H ; Fukuda, H; Furuse, J.A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Apr;48(4):392-395. | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| Mizusawa, J; Fukutomi, A; Katayama, H; Ishii, H ; Ioka, T; Okusaka, T; Ueno, H; Ueno, M; Ikeda, M; Mizuno, N; Ozaka, M; Fukuda, H; Furuse, J.Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).PANCREATOLOGY.2018 Oct;18(7):841-845. | PANCREATOLOGY |
| Suzuki, E; Kaneko, S; Okusaka, T; Ikeda, M; Yamaguchi, K; Sugimoto, R; Aramaki, T; Asagi, A; Yasui, K; Sano, K; Hosokawa, A; Kato, N; Ishii, H ; Sato, T; Furuse, J.A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Apr;48(4):317-321. | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| Makiyama, A; Kunieda, K; Noguchi, M; Kajiwara, T ; Tamura, T; Takeda, K; Sugiyama, J; Minashi, K; Moriwaki, T; Sugimoto, N; Nagase, M; Negoro, Y; Tsuda, T; Shimodaira, H; Okano, N; Tsuji, A; Sakai, D; Yanagihara, K; Ueda, S; Tamura, S; Otsu, S; Honda, T; Matsushita, Y; Okuno, T; Kashiwada, T; Nozaki, A; Ebi, M; Okuda, H; Shimokawa, M; Hironaka, S; Hyodo, I; Baba, E; Boku, N; Muro, K; Esaki, T.First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.GASTRIC CANCER.2018 Sep;21(5):792-801. | GASTRIC CANCER |
| Tsuchihashi, K; Ito, M; Moriwaki, T; Fukuoka, S; Taniguchi, H; Takashima, A; Kumekawa, Y; Kajiwara, T ; Yamazaki, K; Esaki, T; Makiyama, A; Denda, T; Satake, H; Suto, T; Sugimoto, N; Katsumata, K; Ishikawa, T; Kashiwada, T; Oki, E; Komatsu, Y; Okuyama, H; Sakai, D; Ueno, H; Tamura, T; Yamashita, K; Kishimoto, J; Shimada, Y; Baba, E.Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.CLINICAL COLORECTAL CANCER.2018 Dec;17(4):E687-E697. | CLINICAL COLORECTAL CANCER |
| Kodaira, T; Kagami, Y; Shibata, T; Shikama, N; Nishimura, Y; Ishikura, S; Nakamura, K; Saito, Y; Matsumoto, Y; Teshima, T; Ito, Y; Akimoto, T; Nakata, K; Toshiyasu, T; Nakagawa, K; Nagata, Y; Nishimura, T; Uno, T; Kataoka, M ; Yorozu, A; Hiraoka, M.Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study JCOG0701).ANNALS OF ONCOLOGY.2018 Apr;29(4):992-997. | ANNALS OF ONCOLOGY |
| Kubo, T; Ninomiya, T; Hotta, K; Kozuki, T ; Toyooka, S; Okada, H; Fujiwara, T; Udono, H; Kiura, K.Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.CLINICAL LUNG CANCER.2018 Nov;19(6):E861-E864. | CLINICAL LUNG CANCER |
| Fujimoto, N; Aoe, K; Kozuki, T ; Oze, I; Kato, K; Kishimoto, T; Hotta, K.A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.CLINICAL LUNG CANCER.2018 Sep;19(5):E705-E707. | CLINICAL LUNG CANCER |
| Ito, T; Takada, R; Omoto, S; Tsuda, M; Masuda, D; Kato, H; Matsumoto, T ; Moriyama, I; Okabe, Y; Shiomi, H; Ishida, E; Hatamaru, K; Hashimoto, S; Tanaka, K; Kawamoto, H; Yanagisawa, A; Katayama, T; Yazumi, S.Analysis of Prognostic Factors in Pancreatic Metastases: A Multicenter Retrospective Analysis.PANCREAS.2018 Sep;47(8):1033-1039. | PANCREAS |

| | |
|--|--|
| Taniguchi, H; Okamoto, W; Muro, K; Akagi, K; Hara, H; Nishina, T ; Kajiwara, T; Denda, T; Hironaka, S; Kudo, T; Satoh, T; Yamanaka, T; Abe, Y; Fukushima, Y; Yoshino, T.Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.NEOPLASIA.2018 Dec;20(12):1219-1226. | NEOPLASIA |
| Yamaguchi, K; Fujitani, K; Nagashima, F; Omuro, Y; Machida, N; Nishina, T ; Koue, T; Tsujimoto, M; Maeda, K; Satoh, T.Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.GASTRIC CANCER.2018 Nov;21(6):1041-1049. | GASTRIC CANCER |
| Nishina, T ; Takahashi, S; Iwasawa, R; Noguchi, H; Aoki, M; Doi, T.Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.INVESTIGATIONAL NEW DRUGS.2018 Jun;36(3):424-434. | INVESTIGATIONAL NEW DRUGS |
| Yoshino, T; Yamazaki, K; Shinozaki, E; Komatsu, Y; Nishina, T ; Baba, H; Tsuji, A; Tsuji, Y; Yamaguchi, K; Sugimoto, N; Denda, T; Muro, K; Takayama, T; Esaki, T; Hamamoto, Y; Moriwaki, T; Shimada, Y; Goto, M; Nakayama, N; Fujii, H; Tanase, T; Ohtsu, A.Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.CLINICAL COLORECTAL CANCER.2018 Dec;17(4):E719-E732. | CLINICAL COLORECTAL CANCER |
| Tamiya, A; Morimoto, M; Fukuda, S; Naoki, Y; Ibe, T; Okishio, K; Goto, H; Yoshii, A; Kita, T; Nogami, N ; Fujita, Y; Atagi, S.A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer.INVESTIGATIONAL NEW DRUGS.2018 Aug;36(4):667-673. | INVESTIGATIONAL NEW DRUGS |
| Atagi, S; Mizusawa, J; Ishikura, S; Takahashi, T; Okamoto, H; Tanaka, H; Goto, K; Nakagawa, K; Harada, M; Takeda, Y; Nogami, N ; Fujita, Y; Kasai, T; Kishi, K; Sawa, T; Takeda, K; Tomii, K; Satouchi, M; Seto, T; Ohe, Y.Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301).CLINICAL LUNG CANCER.2018 Sep;19(5):E619-E627. | CLINICAL LUNG CANCER |
| Kiura, K; Yoh, K; Katakami, N; Nogami, N ; Kasahara, K; Takahashi, T; Okamoto, I; Cantarini, M; Hodge, R; Uchida, H.Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.CANCER SCIENCE.2018 Apr;109(4):1177-1184. | CANCER SCIENCE |
| Okazawa-Sakai, M ; Yokoyama, T; Fujimoto, E; Okame, S; Shiroyama, Y; Yokoyama, T; Takehara, K.Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY.2018 Aug;23(4):715-725. | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| Miyajima, M; Watanabe, A; Sato, T; Teramukai, S; Ebina, M; Kishi, K; Sugiyama, Y; Kondo, H; Kobayashi, S; Takahashi, Y; Ito, H; Yamamoto, R; Sawada, S ; Fujimori, H; Okabe, K; Arikura, J; Shintani, Y; Nakamura, H; Toyooka, S; Hasumi, T; Watanabe, T; Hata, Y; Iwata, H; Aoki, M; Funai, K; Inoue, S; Kawashima, O; Iida, T; Date, H.What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?.SURGERY TODAY.2018 Apr;48(4):404-415. | SURGERY TODAY |
| Nakata, E; Sugihara, S ; Kataoka, M ; Yamashita, N ; Furumatsu, T; Takigawa, T; Tetsunaga, T; Ozaki, T.Early response assessment of palliative conventional radiotherapy for painful uncomplicated vertebral bone metastases.JOURNAL OF ORTHOPAEDIC SCIENCE.2018 Nov;23(6):912-917. | JOURNAL OF ORTHOPAEDIC SCIENCE |

| | |
|---|--|
| <p>Takabatake, D; Kajiwara, Y; Ohtani, S; Itano, Y; Yamamoto, M; Kubo, S; Ikeda, M; Takahashi, M; Hara, F; Aogi, K; Ohsumi, S; Ogasawara, Y; Nishiyama, Y; Hikino, H; Matsuoka, K; Takahashi, Y; Shien, T; Taira, N; Doihara, H.The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.BREAST CANCER.2018 Nov;25(6):717-722.</p> | <p>BREAST CANCER</p> |
| <p>Matoda, M; Takeshima, N; Michimae, H; Iwata, T; Yokota, H; Torii, Y; Yamamoto, Y; Takehara, K; Nishio, S; Takano, H; Mizuno, M; Takahashi, Y; Takei, Y; Hasegawa, T; Mikami, M; Enomoto, T; Aoki, D; Sugiyama, T.Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).GYNECOLOGIC ONCOLOGY.2018 Jun;149(3):513-519.</p> | <p>GYNECOLOGIC ONCOLOGY</p> |
| <p>Sakurada, S; Watanabe, Y; Tokunaga, H; Takahashi, F; Yamada, H; Takehara, K; Yaegashi, N.Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Sep;48(9):794-798.</p> | <p>JAPANESE JOURNAL OF CLINICAL ONCOLOGY</p> |
| <p>Yano, T; Shimokawa, M; Kawashima, O; Takenoyama, M; Yamashita, Y; Fukami, T; Ueno, T; Yatsuyanagi, E; Fukuyama, S.The influence of comorbidity on the postoperative survival in elderly (>= 75 years old) with lung cancer.GENERAL THORACIC AND CARDIOVASCULAR SURGERY.2018 Jun;66(6):344-350.</p> | <p>GENERAL THORACIC AND CARDIOVASCULAR SURGERY</p> |
| <p>Todaka, A; Mizuno, N; Ozaka, M; Ueno, H; Kobayashi, S; Uesugi, K; Kobayashi, N; Hayashi, H; Sudo, K; Okano, N; Horita, Y; Kamei, K; Yukisawa, S; Nakamori, S; Yachi, Y; Henmi, T; Kobayashi, M; Boku, N; Mori, K; Fukutomi, A.Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.PANCREAS.2018 May;47(5):631-636.</p> | <p>PANCREAS</p> |
| <p>Ohmachi, K; Tobinai, K; Kinoshita, T; Ishikawa, T; Hatake, K; Ichikawa, S; Ohmine, K; Kamitsuji, Y; Choi, I; Chou, T; Tsukasaki, K; Kumagai, K; Taniwaki, M; Uchida, T; Kikukawa, Y; Kubo, K; Mihara, K; Tsukamoto, N; Izutsu, K; Yoshida, I; Ishida, F; Usui, N; Iida, S; Murayama, T; Ueda, E; Kuriki, H; Ando, K.Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.INTERNATIONAL JOURNAL OF HEMATOLOGY.2018 Nov;108(5):499-509.</p> | <p>INTERNATIONAL JOURNAL OF HEMATOLOGY</p> |
| <p>Takase, K; Kada, A; Iwasaki, H; Yoshida, I; Sawamura, M; Yoshio, N; Yoshida, S; Iida, H; Otsuka, M; Takafuta, T; Ogata, Y; Suehiro, Y; Hirabayashi, Y; Hishita, T; Yoshida, C; Ito, T; Hidaka, M; Tsutsumi, I; Saito, AM; Nagai, H.High-dose Dexamethasone Therapy as the Initial Treatment for Idiopathic Thrombocytopenic Purpura: Protocol for a Multicenter, Open-label, Single Arm Trial.ACTA MEDICA OKAYAMA.2018 Apr;72(2):197-201.</p> | <p>ACTA MEDICA OKAYAMA</p> |
| <p>Miyata, Y; Saito, AM; Yano, T; Yoshida, I; Suehiro, Y; Harada, N; Nagai, H.R-mini CHP in >= 80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol.ACTA MEDICA OKAYAMA.2018 Jun;72(3):315-318.</p> | <p>ACTA MEDICA OKAYAMA</p> |
| <p>Doi, Toshihiko; Iwasa, Satoru; Muro, Kei; Satoh, Taroh; Hironaka, Shuichi; Esaki, Taito; Nishina, Tomohiro; Hara, Hiroki; Machida, Nozomu; Komatsu, Yoshito; Shimada, Yasuhiro; Otsu, Satoshi; Shimizu, Shin; Watanabe, Morihiro.Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial..Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.2018.;</p> | <p>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</p> |

| | |
|--|--|
| Hata, Akito; Harada, Daijiro ; Okuda, Chiyuki; Kaji, Reiko; Masuda, Yoshio; Takechi, Yoshika; Kozuki, Toshiyuki; Nogami, Naoyuki; Katakami, Nobuyuki.Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer..Oncotarget.2018 Jun;9(45):27789-27796. | Oncotarget |
| Kishi, Kazuma; Sakai, Hiroshi; Seto, Takashi; Kozuki, Toshiyuki ; Nishio, Makoto; Imamura, Fumio; Nokihara, Hiroshi; Satouchi, Miyako; Nakagawa, Shintaro; Tahata, Takashi; Nakagawa, Kazuhiko.First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer..Cancer treatment and research communications.2019.;100113 | Cancer treatment and research communications |
| Kuroda, Shinji; Choda, Yasuhiro; Otsuka, Shinya; Ueyama, Satoshi; Tanaka, Norimitsu; Muraoka, Atsushi; Hato, Shinji ; Kimura, Toshikazu; Tanakaya, Kohji; Kikuchi, Satoru; Tanabe, Shunsuke; Noma, Kazuhiro; Nishizaki, Masahiko; Kagawa, Shunsuke; Shirakawa, Yasuhiro; Kamikawa, Yasuaki; Fujiwara, Toshiyoshi.Multicenter retrospective study to evaluate the efficacy and safety of the double-flap technique as antireflux esophagogastrostomy after proximal gastrectomy (rD-FLAP Study)..Annals of gastroenterological surgery.2019 Jan;3(1):96-103. | Annals of gastroenterological surgery |
| Matsuzuka, Takashi; Kiyota, Naomi; Mizusawa, Junki; Akimoto, Tetsuo; Fujii, Masato; Hasegawa, Yasuhisa; Iwae, Shigemichi; Monden, Nobuya ; Matsuura, Kazuto; Onozawa, Yusuke; Hayashi, Ryuichi; Tahara, Makoto.Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2)..Japanese journal of clinical oncology.2019 Jan;49(1):37-41. | Japanese journal of clinical oncology |
| Nogami, Naoyuki ; Nishio, Makoto; Okamoto, Isamu; Enatsu, Sotaro; Suzukawa, Kazumi; Takai, Hiroki; Nakagawa, Kazuhiko; Tamura, Tomohide.Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients..Respiratory investigation.2019 Jan;57(1):27-33. | Respiratory investigation |
| Shimizu, Kimihiro; Ohtaki, Yoichi; Okumura, Takehiro; Boku, Narikazu; Horio, Hiroto; Takenoyama, Mitsuhiro; Yamashita, Motohiro ; Hyodo, Ichinosuke; Mori, Keita; Kondo, Haruhiko.Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases..The Journal of thoracic and cardiovascular surgery.2019.; | The Journal of thoracic and cardiovascular surgery |
| Morizane, C; Ueno, M; Ikeda, M; Okusaka, T; Ishii, H ; Furuse, J.New developments in systemic therapy for advanced biliary tract cancer.JAPANESE JOURNAL OF CLINICAL ONCOLOGY.2018 Aug;48(8):703-711. | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| Ohe, Yuichiro; Imamura, Fumio; Nogami, Naoyuki ; Okamoto, Isamu; Kurata, Takayasu; Kato, Terufumi; Sugawara, Shunichi; Ramalingam, Suresh S; Uchida, Hirohiko; Hodge, Rachel; Vowler, Sarah L; Walding, Andrew; Nakagawa, Kazuhiko.Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset..Japanese journal of clinical oncology.2019 Jan;49(1):29-36. | Japanese journal of clinical oncology |
| M. Kochi, T. Hinoi, H. Niitsu, H. Ohdan, F. Konishi, Y. Kinugasa, T. Kobatake , M. Ito, M. Inomata, T. Yatsuoka, T. Ueki, J. Tashiro, S. Yamaguchi, M. Watanabe and C. Japan Soc Laparoscopic.Risk factors for postoperative pneumonia in elderly patients with colorectal cancer: a sub-analysis of a large, multicenter, case-control study in Japan.Surgery Today.2018 Aug;48(8):756-764. | Surgery Today |

| | |
|---|---|
| <p>K. Nakajima, G. Kaneko, S. Takahashi, H. Matsuyama, H. Shiina, T. Ichikawa, H. Horikoshi, K. Hashine, Y. Sugiyama, T. Miyao, M. Kamiyama, K. Harada, A. Ito, A. Mizokami and P.-B. Investigators. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study. 2018 May; 25(5):492-499.</p> | <p>International Journal of Urology</p> |
| <p>M. Nakatochi, Y. S. Lin, H. Ito, K. Hara, F. Kinoshita, Y. Kobayashi, H. Ishii, M. Ozaka, T. Sasaki, N. Sasahira, M. Morimoto, S. Kobayashi, M. Ueno, S. Ohkawa, N. Egawa, S. Kuruma, M. Mori, H. Nakao, C. C. Wang, T. Nishiyama, T. Kawaguchi, M. Takahashi, F. Matsuda, S. Kikuchi and K. Matsuo. Prediction model for pancreatic cancer risk in the general Japanese population. 2018 Sep; 13(9):13.</p> | <p>Plos One</p> |
| <p>R. Nishimura, Y. Murata, K. Mori, K. Yamashiro, K. Kuraoka, S. Ichihara, K. Taguchi, H. Suzuki, M. Ito and N. Yamashita. Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study. 2018; 62(4):288-294.</p> | <p>Acta Cytologica</p> |
| <p>T. Reungwetwattana, K. Nakagawa, B. C. Cho, M. Cobo, E. K. Cho, A. Bertolini, S. Bohnet, C. C. Zhou, K. H. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, A. P. Brown, Y. Rukazenzov, S. S. Ramalingam and J. Vansteenkiste. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. 2018 Aug 28; JCO2018783118.</p> | <p>Journal of Clinical Oncology</p> |
| <p>T. Sasaki, T. Seto, T. Yamanaka, N. Kunitake, J. Shimizu, T. Kodaira, M. Nishio, T. Kozuka, T. Takahashi, H. Harada, N. Yoshimura, S. Tsutsumi, H. Kitajima, M. Kataoka, Y. Ichinose, K. Nakagawa, Y. Nishimura, N. Yamamoto and Y. Nakanishi. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. British Journal of Cancer. 2018 Sep; 119(6):675-682.</p> | <p>British Journal of Cancer</p> |
| <p>A. Sawaki, Y. Yamada, K. Yamaguchi, T. Nishina, T. Doi, T. Satoh, K. Chin, N. Boku, Y. Omuro, Y. Komatsu, Y. Hamamoto, W. Koizumi, S. Saji, M. A. Shah, E. Van Cutsem, Y. K. Kang, J. Iwasaki, H. Kuriki, W. Ohtsuka and A. Ohtsu. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Gastric Cancer. 2018 May; 21(3):429-438.</p> | <p>Gastric Cancer</p> |
| <p>T. Seto, N. Nogami, N. Yamamoto, S. Atagi, N. Tashiro, Y. Yoshimura, Y. Yabuki and H. Saka. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. Oncology and Therapy. 2018 Dec; 6(2):203-215.</p> | <p>Oncology and Therapy</p> |
| <p>S. Shiba, H. Imaoka, K. Shioji, E. Suzuki, S. Horiguchi, T. Terashima, Y. Kojima, T. Okuno, Y. Sukawa, K. Tsuji, K. Umemoto, A. Asagi, A. Todaka, M. Ueno, M. Ikeda, C. Morizane and J. Furuse. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer. 2018 Oct; 18(0):7.</p> | <p>Bmc Cancer.</p> |
| <p>M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C. A. Thomas, F. Barlesi, G. Finley, C. Kelsch, A. Lee, S. Coleman, Y. Deng, Y. Shen, M. Kowanzet, A. Lopez-Chavez, A. Sandler, M. Reck and I. M. S. Grp. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine. 2018 Jun; 378(24):2288-2301.</p> | <p>New England Journal of Medicine</p> |

| | |
|--|--|
| <p>N. Takata, M. Kataoka, Y. Hamamoto, S. Tsuruoka, H. Kanzaki, K. Uwatsu, K. Nagasaki and T. Mochizuki. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique. <i>Journal of Radiation Research</i>. 2018 May;59(3):291-297.</p> | <p>Journal of Radiation Research</p> |
| <p>F. Tanaka, H. Yokomise, T. Soejima, H. Uramoto, T. Yamanaka, K. Nakagawa, N. Yamamoto, Y. Nishimura, H. Niwa, M. Okada, T. Nakagawa and M. Yamashita. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i>. 2018 Oct;106(4):1018-1024.</p> | <p>Annals of Thoracic Surgery</p> |
| <p>S. Toyooka, N. Okumura, H. Nakamura, M. Nakata, M. Yamashita, H. Tada, S. Kajiwara, N. Watanabe, M. Okada, J. Sakamoto, M. Aoe, J. Soh, S. Miyoshi, K. Hotta, K. Matsuo and H. Date. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i>. 2018 May;13(5):699-706.</p> | <p>Journal of Thoracic Oncology</p> |
| <p>A. Valachis, E. P. Mamounas, E. A. Mittendorf, N. Hayashi, M. Ishitobi, C. Natoli, F. Fitzal, I. T. Rubio, D. G. Tiezzi, H. C. Shin, S. J. Anderson, K. K. Hunt, N. Matsuda, S. Ohsumi, A. Totomi and C. Nilsson. Risk Factors for Locoregional Disease Recurrence After Breast-Conserving Therapy in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy: An International Collaboration and Individual Patient Meta-Analysis. <i>Cancer</i>. 2018 Jul;124(14):2923-2930.</p> | <p>Cancer</p> |
| <p>M. Yokoi, D. Tsuji, K. Suzuki, Y. Kawasaki, M. Nakao, H. Ayuhara, Y. Kogure, K. Shibata, T. Hayashi, K. Hirai, K. Inoue, T. Hama, K. Takeda, M. Nishio and K. Itoh. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. <i>Supportive Care in Cancer</i>. 2018 May;26(5):1505-1513.</p> | <p>Supportive Care in Cancer</p> |
| <p>B. C. Cho, B. Chewaskulyong, K. H. Lee, A. Dechaphunkul, V. Sriuranpong, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, C. C. Zhou, Y. Cheng, E. K. Cho, P. J. Voon, J. S. Lee, H. Mann, M. Saggese, T. Reungwetwattana, S. S. Ramalingam and Y. Ohe. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i>. 2019 Jan;14(1):99-106.</p> | <p>Journal of Thoracic Oncology</p> |
| <p>T. Denda, D. Sakai, T. Hamaguchi, N. Sugimoto, T. Ura, K. Yamazaki, H. Fujii, T. Kajiwara, T. E. Nakajima, S. Takahashi, S. Otsu, Y. Komatsu, F. Nagashima, T. Moriwaki, T. Esaki, T. Sato, M. Itabashi, E. Oki, T. Sasaki, Y. Sunaga, S. Ziti-Ljajic, C. Brillac and T. Yoshino. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i>. 2019 Mar;110(3):1032-1043.</p> | <p>Cancer Science</p> |
| <p>E. Fujimoto, K. Takehara, T. Tanaka, T. Yokoyama, K. Tomono, M. Okazawa-Sakai, S. Okame, Y. Sugawara and N. Teramoto. Uterine leiomyosarcoma well-controlled with eribulin mesylate. <i>International Cancer Conference Journal</i>. 2019 Jan;8(1):33-38.</p> | <p>International Cancer Conference Journal</p> |
| <p>M. Hinata, K. Miyazaki, N. Kanazawa, K. Kito, S. Kiyoto, M. Konda, A. Kuriyama, H. Mori, S. Nakaoka, A. Okumura, H. Tokumasu and T. Nakayama. Trends in descriptions of palliative care in the cancer clinical practice guidelines before and after enactment of the Cancer Control Act (2007): content analysis. <i>Bmc Palliative Care</i>. 2019 Jan;18(0):8.</p> | <p>Bmc Palliative Care</p> |

| | |
|--|---|
| <p>K. Kato, T. Satoh, K. Muro, T. Yoshikawa, T. Tamura, Y. Hamamoto, K. Chin, K. Minashi, M. Tsuda, K. Yamaguchi, N. Machida, T. Esaki, M. Goto, Y. Komatsu, T. E. Nakajima, N. Sugimoto, K. Yoshida, E. Oki, T. Nishina, A. Tsuji, H. Fujii, K. Kunieda, S. Saitoh, Y. Omuro, M. Azuma, Y. Iwamoto, K. Taku, S. Fushida, L. T. Chen, Y. K. Kang and N. Boku. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i>. 2019 Mar;22(2):344-354.</p> | <p>Gastric Cancer</p> |
| <p>D. Maruyama, K. Tsukasaki, T. Uchida, Y. Maeda, H. Shibayama, H. Nagai, M. Kurosawa, Y. Suehiro, K. Hatake, K. Ando, I. Yoshida, M. Hidaka, T. Murayama, Y. Okitsu, N. Tsukamoto, M. Taniwaki, J. Suzumiya, K. Tamura, T. Yamauchi, R. Ueda and K. Tobinai. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. <i>Annals of Hematology</i>. 2019 Jan;98(1):131-142.</p> | <p>Annals of Hematology</p> |
| <p>N. Masuda, K. Inoue, R. Nakamura, Y. Rai, H. Mukai, S. Ohno, F. Hara, Y. Mori, S. Hashigaki, Y. Muramatsu, T. Nagasawa, Y. Umeyama, X. Huang and H. Iwata. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. <i>Int J Clin Oncol</i>. 2019 Mar;24(3):262-273.</p> | <p>Int J Clin Oncol</p> |
| <p>I. Matsumoto, K. Kamei, K. Omae, S. Suzuki, H. Matsuoka, N. Mizuno, M. Ozaka, H. Ueno, S. Kobayashi, K. Uesugi, M. Kobayashi, A. Todaka and A. Fukutomi. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nationwide multicenter observational study in Japan. <i>Pancreatology</i>. 2019 Mar;19(2):296-301.</p> | <p>Pancreatology</p> |
| <p>H. Mukai, C. Shimizu, N. Masuda, S. Ohtani, S. Ohno, M. Takahashi, Y. Yamamoto, R. Nishimura, N. Sato, S. Ohsumi, H. Iwata, Y. Mori, S. Hashigaki, Y. Muramatsu, T. Nagasawa, Y. Umeyama, D. R. R. Lu and M. Toi. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i>. 2019 Mar;24(3):274-287.</p> | <p>International Journal of Clinical Oncology</p> |
| <p>E. Nakata, S. Sugihara, M. Kataoka, N. Yamashita, T. Furumatsu, T. Takigawa, T. Tetsunaga and T. Ozaki. Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. <i>Journal of Orthopaedic Science</i>. 2019 Mar;24(2):332-336.</p> | <p>Journal of Orthopaedic Science</p> |
| <p>T. Nishina, M. Azuma, K. Nishikawa, M. Gotoh, H. Bando, N. Sugimoto, K. Amagai, K. Chin, Y. Niwa, A. Tsuji, H. Imamura, M. Tsuda, H. Yasui, H. Fujii, K. Yamaguchi, H. Yasui, S. Hironaka, K. Shimada, H. Miwa, T. Mitome, H. Kageyama and I. Hyodo. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. <i>Gastric Cancer</i>. 2019 Jan;22(1):138-146.</p> | <p>Gastric Cancer</p> |
| <p>M. Nozaki, Y. Kagami, T. Shibata, K. Nakamura, Y. Ito, Y. Nishimura, Y. Kawaguchi, Y. Saito, Y. Nagata, Y. Matsumoto, T. Akimoto, M. Hiraoka, T. Nishimura, T. Uno, K. Tsujino, M. Kataoka, T. Kodaira, K. Shiraishi, K. Inoue, F. Isohashi, K. Karasawa, S. Izumi, H. Sakurai, N. Shikama, K. Hayakawa, H. Onishi, M. Tanaka, T. Toita, G. Radiation Therapy Study and G. Japan Clinical Oncology. A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. <i>Japanese Journal of Clinical Oncology</i>. 2019 Jan;49(1):57-62.</p> | <p>Japanese Journal of Clinical Oncology</p> |

| | |
|--|---|
| <p>H. Shirasu, A. Todaka, K. Omae, H. Fujii, N. Mizuno, M. Ozaka, H. Ueno, S. Kobayashi, K. Uesugi, N. Kobayashi, H. Hayashi, K. Sudo, N. Okano, Y. Horita, K. Kamei, S. Yukisawa, M. Kobayashi and A. Fukutomi. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. <i>Cancer Science</i>. 2019 Feb;110(2):707-716.</p> | <p>Cancer Science</p> |
| <p>H. Suzuki, K. Takizawa, T. Hirasawa, Y. Takeuchi, K. Ishido, S. Hoteya, T. Yano, S. Tanaka, M. Endo, M. Nakagawa, T. Toyonaga, H. Doyama, K. Hirasawa, M. Matsuda, H. Yamamoto, M. Fujishiro, S. Hashimoto, Y. Maeda, T. Oyama, R. Takenaka, Y. Yamamoto, Y. Naito, T. Michida, N. Kobayashi, Y. Kawahara, M. Hirano, M. Jin, S. Hori, Y. Niwa, T. Hikichi, T. Shimazu, H. Ono, S. Tanabe, H. Kondo, H. Iishi, M. Ninomiya, I. Oda and J. W. E. Grp. Short-term outcomes of multicenter prospective cohort study of gastric endoscopic resection: 'Real-world evidence' in Japan. <i>Digestive Endoscopy</i>. 2019 Jan;31(1):30-39.</p> | <p>Digestive Endoscopy</p> |
| <p>K. Yonemori, A. Shimomura, H. Yasojima, N. Masuda, K. Aogi, M. Takahashi, Y. Naito, S. Shimizu, R. Nakamura, J. Hashimoto, H. Yamamoto, A. Hirakawa, H. Michimae, A. Hamada, T. Yoshida, T. Sukigara, K. Tamura and Y. Fujiwara. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i>. 2019 Mar;109(0):84-91.</p> | <p>European Journal of Cancer</p> |
| <p>T. Yoshikawa, M. Terashima, J. Mizusawa, S. Nunobe, Y. Nishida, T. Yamada, M. Kaji, N. Fukushima, S. Hato, Y. Choda, H. Yabusaki, K. Yoshida, S. Ito, A. Takeno, T. Yasuda, Y. Kawachi, H. Katayama, H. Fukuda, N. Boku, T. Sano and M. Sasako. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 OPAS-1): an open-label, phase 3, non-inferiority, randomised trial. <i>Lancet Gastroenterology & Hepatology</i>. 2019 Mar;4(3):208-216.</p> | <p>Lancet Gastroenterology & Hepatology</p> |
| <p>S. Zenda, Y. Ota, N. Kiyota, S. Okano, M. Fujii, M. Kitamura, S. Takahashi, T. Ueda, N. Monden, T. Yamanaka and M. Tahara. A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEX) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). <i>Frontiers in Oncology</i>. 2019 Jan;9(0);7.</p> | <p>Frontiers in Oncology</p> |
| <p>Ninomiya, Takashi; Ishikawa, Nobuhisa; Inoue, Koji; Kubo, Toshio; Yasugi, Masayuki; Shibayama, Takuo; Maeda, Tadashi; Fujitaka, Kazunori; Kodani, Masahiro; Yokoyama, Toshihide; Kuyama, Shoichi; Ochi, Nobuaki; Ueda, Yutaka; Miyoshi, Seigo; Kozuki, Toshiyuki; Amano, Yoshihiro; Kubota, Tetsuya; Sugimoto, Keisuke; Bessho, Akihiro; Ishii, Tomoya; Watanabe, Kazuhiko; Oze, Isao; Hotta, Katsuyuki; Kiura, Katsuyuki. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. <i>Clinical lung cancer</i>. 2019 Mar;20(2):134-138.</p> | <p>Clinical Lung Cancer</p> |
| <p>Yokoyama, T; Takehara, K; Sugimoto, N; Kaneko, K; Fujimoto, E; Okazawa-Sakai, M; Okame, S; Shiroyama, Y; Yokoyama, T; Teramoto, N; Ohsumi, S; Saito, S; Imai, K; Sugano, K. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review. <i>BMC CANCER</i>. 2018 May 21;18(1):576.</p> | <p>BMC CANCER</p> |
| <p>Yoshida K, Miyagawa M, Kido T, Ide K, Sano Y, Sugawara Y, Takahata H, Monden N, Furuya M, Mochizuki T. Parotid oncocytoma as a manifestation of Birt-Hogg-Dube syndrome. <i>Case Rep Radiol</i>. 2018 Jun 3;2018:6265175.</p> | <p>Case Rep Radiol</p> |

| | |
|---|-----------------------------------|
| Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K , Sasano H, Toi M.Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.ESMO Open. 2019 Feb 27;4(1):e000476. | ESMO Open |
| Kobayashi S, Ueno M, Omae K, Kuramochi H, Terao M, Mizuno N, Ozaka M, Ueno H, Uesugi K , Kobayashi N, Kobayashi M, Todaka A, Fukutomi A.Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer.Oncotarget. 2019 Mar 5;10(19):1775-1784. | ONCOTARGET |
| Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A , Takagi M, Boku N, Sano T, Sasako M.Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).Gastric Cancer. 2019 Mar 2. doi: 10.1007/s10120-019-00941-z. [Epub ahead of print]. | Gastric Cancer |
| Uraguchi K, Kariya S, Makihara S, Oka A , Ueeda H, Noda Y, Nishizaki K.Dangerous noodle: A case of swallowing syncope and a review of 122 cases from the literature.J Arrhythm. 2018 Nov 1;35(1):145-148. | J Arrhythm |
| Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, Hara F , Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Huang X, Iwata H.Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.Int J Clin Oncol. 2019 Mar;24(3):262-273. | Int J Clin Oncol |
| Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I , Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K.Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.Ann Hematol. 2018 Dec;97(12):2529-2530. | Ann Hematol |
| 牧佑歩, 原田大二郎, 山下素弘. 第2章がんを知る禁煙のすすめニコチン依存症と闘う. 第4章がんと闘う最新・最良の医療を目指して肺がんと闘う進歩し続ける治療、増え続ける選択肢. 第5章がんと共に生きるがんと補完代替療法民間療法などは具体的な資料を持って担当医に相談しましょう. 第6章がん診療の明日がん診療の明日患者さんと家族を専門家によるチーム医療で支えています. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜. 2019 ; 44 82-85 135 138-139 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 岡崎ちか、佐伯梓、鎌田裕子 がん患者の「食」をサポート -管理栄養士としての関わり- 医療 2018 ; vol72 No.10 419-423 | 医療 |
| 久保 知之. がん患者にみらせる「皮膚・局所」の症状 血管痛 血管外漏出、がん患者の症状まるわかり BOOK,2018:394-462 昭林社 | がん患者の症状まるわかり BOOK |
| 池辺琴映、岸田恵、土居美幸. 患者の悩み・疑問に答えるアピアランスケア「髪を洗っていたら、縮んでしまいました。どうすればよいですか?」。 がん看護. 2018 ; 23巻4号 : 385-388 | がん看護 |
| 菊内由貴. 看護師の「教え方」看護師育成入門(第10回) エキスパートになるために(熟達者)教育事例 がん看護に強い看護師育成研修の評価と課題(解説). ナーシング2018 ; 38 (10) : 96-100 | ナーシング |
| 菊内由貴. 【教える自信がつく!効果がみえる!教え方&指導術〜新人・若手看護師編〜】 (Part 2)これだけは知っておきたい!「教え方」のポイント(解説/特集). ナース専科2018 ; 38 (4) : 52-56 | ナース専科 |

| | |
|--|---------------------------------------|
| 菊内由貴,看護師の「教え方」 看護師育成入門(第6回) 中堅看護師育成(中堅者) 中堅看護師ってどんな人?教育・学習支援におけるポイントは?(解説). ナーシング2018 ; 38 (6) : 96-101 | ナーシング |
| 岡本奈美, 西村理恵子, 佐藤正和, 山本珠美, 田中慎一. セルブロック法を用いた乳癌受容体検査に使用できる液化化検体細胞診専用固定液の検討. 日臨細胞誌2018 ; 57(6):281-287 | 日本臨床細胞学会雑誌 |
| 羽藤慎二, 香川哲也, 落合亮二, 御厨美洋, 小林成行, 小島誉也, 大田耕司, 野崎功雄. スキルス胃癌に対する審査腹腔鏡の意義. 外科. 2019 ; 81 : 29-33 | 外科 |
| 野崎功雄, 梶原猛史, 羽藤慎二, 香川哲也, 落合亮二, 浅木彰則, 大田耕司. 第4章がんと闘う最新・最良の医療を目指して食道がんと闘う手術だけではない、病状にあわせたさまざまな治療法について. 第4章がんと闘う最新・最良の医療を目指して胃がんと闘う 豊富な経験と最新の技術を融合させた外科治療. 第4章がんと闘う最新・最良の医療を目指して大腸がんと闘う一人ひとりの患者さんに合った治療戦略を目指して. 第4章がんと闘う最新・最良の医療を目指して肝・胆・膵がんと闘う最新治療とチーム医療で難治性のがんに挑む. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜. 2019 ; 90-91 92-93 94-95 96-99 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 堀伸一郎, 金子景香, 松山裕美, 宮脇聡子, 井上実穂, 竹原和宏, 小林成行, 大住省三. 病歴聴取からリンチ症候群を疑い確定診断に至った早期直腸癌の1例. 家族性腫瘍 2018 ; 18 : 8-11 | 家族性腫瘍 |
| 仁科智裕. レゴラフェニブのリアルワールドデータ - CONSIGN研究, REBACCA研究, 本邦における前向き観察研究 -. 大腸癌に対するレゴラフェニブ治療 2019 ; 60-66. 吉野孝之. (株)アークメディア. 東京 | 大腸癌に対するレゴラフェニブ治療 |
| 杉原進介, 魚谷弘二, 中田英二, 尾崎敏文 骨転移登録システム稼働後に発生した最近の対麻痺症例の検討. 中部日本整形外科災害外科学会雑誌 2018 ; 61 : 1105-1106 | 中部日本整形外科災害外科学会雑誌 |
| 明崎 禎輝, 中田 英二, 富永 律子, 黒河 英彰, 菊内 祐人, 濱田 麻紀子, 魚谷 弘二, 杉原 進介 リハビリテーション介入における病的骨折リスクマネージメントの効果 病的骨折リスクの高い乳がん骨転移を伴った患者 : 保健医療学雑誌 2018 ; 9 : 39-44 | 保健医療学雑誌 |
| 青儀健二郎. 第1部 臨床編. 臨床・病理 乳癌取扱い規約 第18版 2018 ; 2-6 | 臨床・病理 乳癌取扱い規約 第18版 |
| 大住省三, 青儀健二郎, 高嶋成輝, 高橋三奈, 原 文堅, 清藤佐知子, 松山裕美, 金子景香. 当院での遺伝性乳癌卵巣癌(HBOC)乳癌未発症での乳房サーベイランス実施状況. 日本乳癌検診学会誌 2018 ; 27 : 24-28 | 日本乳癌検診学会誌 |
| 青儀健二郎, 清水弥生, 宮内一恵, 羽藤慎二, 河村 進. 乳癌化学療法クリニカルパス改善に向けたレジメン別パリアンス分析. 日本クリニカルパス学会誌 2018 ; 20 : 141-144 | 日本クリニカルパス学会誌 |
| 大住省三. 脱毛予防のための頭皮冷却療法. Cancer Board Square 2018 ; 4 : 82-85 | Cancer Board Square |
| 青儀健二郎. 第1章 総論 4.職種ごとの役割や連携することの意義, 第2章 各施設の研究・調査結果 班研究の目的, 四国がんセンターにおける研究・調査の結果, 第3章 Q&A Q3 メディカルサーベイランスとは何ですか?, Q11 HDでブラッキングせざるを得ないときがあります. どのようなことに注意すべきでしょうか?. 抗がん薬曝露対策ファイル NHOネットワーク共同研究参加32施設からの提言 2018 ; 12-14, 24-32, 75-80, 95-96, 114-116 | 抗がん薬曝露対策ファイル NHOネットワーク共同研究参加32施設からの提言 |
| 原 文堅. II 臨床腫瘍学の基礎 4.分子標的治療薬概論 B)小分子化合物 (13)PARP阻害薬, C)抗体薬 (3)抗HER2抗体薬, III 臨床腫瘍学の実践 23乳がん. 新臨床腫瘍学 (改訂第5版) :がん薬物療法専門医のために 2018 ; 332-333, 343-347, 429-441 | 新臨床腫瘍学 (改訂第5版) :がん薬物療法専門医のために |
| 大住省三. Skin-sparing Mastectomy(SSM)とNipple-sparing Mastectomy(NSM)の現状. Oncoplastic Breast Surgery 2018 ; 3 : 1-6 | Oncoplastic Breast Surgery |
| 大住省三. 遺伝性乳がん卵巣がん症候群に対するリスク低減手術. 腫瘍内科 2018 ; 23 : 334-341 | 腫瘍内科 |
| 原 文堅. 乳がんの新しいtargeted therapy : CDK4/6, PI3K, and AKT. 腫瘍内科 2018 ; 22 : 278-285 | 腫瘍内科 |

| | |
|---|-----------------------------------|
| 青儀健二郎. II章 薬物療法の実践 A術前・術後薬物療法 a化学療法 6.classical CMF(後), 7.tegafur・uracil(後). 乳がん薬物療法ハンドブック 2019 | 乳がん薬物療法ハンドブック |
| 大住省三. 第1章 がん専門病院ができること 家族性腫瘍相談室 遺伝子的にがんにかかりやすい体質を持った方のために. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 22-23 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 青儀健二郎. 第1章 がん専門病院ができること 原発不明がん外来 早い診断、早い治療開始を目指して. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 28-29 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 大住省三. 第2章 がんを知る 生活習慣と乳がん 乳がんにならない生活. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 45-45 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 高嶋成輝. 第3章 がんを見つける 病院での診断・外来編. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 54-55 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 大住省三, 河村 進. 第4章 がんと闘う 最新・最良の医療を目指して 乳がんと闘う 最先端の機器、充実したスタッフで最良の治療を. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 78-81 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 清藤佐知子. 第5章 がんと共に生きる 外見の変化に対するケア あなたらしくいられるように. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 128-128 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 高橋三奈. 第5章 がんと共に生きる Topics6 子どもを持ちたい方へ. がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 2019 ; 136-136 | がん専門病院からのメッセージ〜がんと闘い、共に生きる人を支えたい〜 |
| 成本勝広. 地域連携の問題点と対策. 腫瘍内科 2018 ; 21 (4) : 505-510 | 腫瘍内科 |
| 藤山 幹子. 第3章 見逃してほしくないこどもの皮膚疾患 A 固定薬疹. B 重症薬疹の初期症状. 大嶋勇成、宮地良樹 編集. こどもの皮膚疾患. 東京. 診断と治療社. P334-339. | こどもの皮膚疾患 |
| 藤山 幹子. 薬剤性過敏症症候群とHHV-6. 消化器・肝臓内科 2019; 27: 365-370. | 消化器・肝臓内科 |
| 竹原 和宏、婦人科外来がん患者の術後補助化学療法における脱毛に関する思いや不安と対処行動 | 中国四国地区国立病院機構・国立療養所看護研究会誌 |
| 菅 雅世、平田 早苗、高木 泰代、岸田 恵、村上 直子、竹原 和宏、婦人科外来がん患者の術後補助化学療法における脱毛に関する思いや不安と対処行動、中国四国地区国立病院機構・国立療養所看護研究会誌、2018、13:227-230 | 中国四国地区国立病院機構・国立療養所看護研究会誌 |
| 竹原 和宏、婦人科がん(第2版) - 最近の動向 -、子宮体癌の発生 (3)子宮体がんの発症リスク、日本臨牀、2018、76(増刊号2) ,373-377 | 日本臨牀 |
| 竹原 和宏、特集 卵巣癌の手術update 進行例に対する後腹膜リンパ節郭清(LION)の意義とこれから、産婦人科の実際、2018、67(5):479-484 | 産婦人科の実際 |
| 竹原 和宏、特集 難治性婦人科悪性腫瘍の臨床最前線 1.子宮平滑筋肉腫治、産婦人科の実際、2018、67(7):709-713 | 産婦人科の実際 |
| 横山 貴紀、大亀 真一、友野 勝幸、藤本 悦子、坂井 美佳、横山 隆、竹原 和宏、寺本典弘、卵巣漿液性癌における腹水細胞診のピットフォール -低悪性度漿液性癌-、日本婦人科腫瘍学会雑誌、2018、In Pless | 日本婦人科腫瘍学会雑誌 |
| 友野 勝幸、横山 貴紀、藤本 悦子、(坂井 美佳)、大亀 真一、(横山 隆)、竹原 和宏、腹腔鏡下後腹膜腫瘍摘出術が診断の契機となった卵管癌の1例、現代産婦人科、2018、66(2):317-322 | 現代産婦人科 |

| | |
|--|---------------------------------|
| 森 俊太、野上 尚之. 【肺がん】 第3世代EGFR-TKIは標準的初回治療になるか?Pros. 腫瘍内科、21巻5号 Page516-522. | 腫瘍内科 |
| 森 俊太、野上 尚之. 変異特異的に作用する新たなEGFR-TKIの効果. がん分子標的治療 (1347-6955)16巻2号 Page213-215 | がん分子標的治療 |
| 山本雄太, 菅原敬文, 橋根勝義, 寺本典弘. 管状嚢胞腎細胞癌の1例. 臨床放射線63:1031-1034, 2018 | 臨床放射線 |
| 宮脇聡子. 【特集】日本遺伝看護学会第17回学術大会より〔シンポジウム：臨床における遺伝看護の普及と教育の在り方〕がん看護専門看護師（OCNS）による看護師の遺伝に関する役割開発と教育,日本遺伝看護学会誌,2019,18 (2),27-31 | 日本遺伝学会誌 |
| 吉田 功、造血管腫瘍におけるfilgrastimおよびrituximabのバイオ後続品に関するエビデンス | 血液内科 77(6):800-805,2018 |
| 吉田 功、非Hodgkinリンパ腫の予後予測因子 | 病理と臨床 2019, vol.37,no3.221-227. |
| 寺本典弘,病理医と臨床医で解説する婦人科腫瘍 外陰癌の病理と臨床 外陰癌の病理と臨床・病理篇 | 婦人科腫瘍学会誌 |
| 門田 伸也,【どこが変わった頭頸部癌診療ガイドライン】 甲状腺癌,2018,90巻10号 Page832-836 | 耳鼻咽喉科・頭頸部外科 |
| 橋本 香里,門田 伸也,【手術に必要な画像診断-喉頭・気管編】 気管孔開大術,2018,34巻6号 Page763-768 | JOHNS |
| 岡 愛子、門田 伸也、橋本 香里、花川 浩之,甲状腺葉切除後の甲状腺機能低下についての検討,2018,111巻1号 Page61-65 | 耳鼻咽喉科臨床 |
| 綱島千春、河村進、時吉貴宏 人工物を用いた乳房再建後感染症例への対応－人工物を抜去しない救済処置で感染制御は可能か－ Oncoplastic Brest surgery 2(3):71-77.2017 | Oncoplastic Brest surgery |
| 山本雄太、橋根勝義、管状嚢胞腎細胞癌の1例、臨床放射線.63； 1031-1034、2018 | 臨床放射線 |